Artificial intelligence (AI) software developer RapidAI has garnered U.S. Food and Drug Administration (FDA) clearance for its Rapid ASPECTS stroke imaging computer-aided diagnosis (CADx) software.
Based on the Alberta Stroke Program Early CT Scoring (ASPECTS) system, Rapid ASPECTS employs a machine-learning algorithm to automatically identify the ASPECTS regions of the brain on noncontrast CT exams. In a few minutes, the software then generates an ASPECT score to indicate early signs of brain infarction, the company said.
By automating and standardizing the process of identifying areas of irreversible brain injury, Rapid ASPECTS can improve the accuracy of nonexpert readers and help stroke teams to quickly assess patient eligibility for thrombectomy, enabling faster triage and transfer decisions, according to the vendor.
